Orchard to open CA plant in 2021 to support gene therapy pipeline
Orchard Therapeutics says it will balance its existing CMO network with a planned facility in Fremont to create the infrastructure needed to commercialize its gene therapies. Orchard’s pipeline of ex vivo autologous gene therapies include the former GSK hematopoietic stem cell (HSC) gene ther ...
CDMO Samsung BioLogics has used an Alternating Tangential Flow (ATF) system to perform N-1 perfusion at its 180,000 L facility in South Korea.
...
Months after buying platform firm Just.Bio, Evotec says it is evaluating the construction of the first modular J.POD for commercial manufacturing ...
Zealand Pharma has taken its first steps to build US commercial operations with an aim to launch four peptides over the next five years.
Accor ...
With potentially three acquisitions within nine months, Agilent Technologies has rapidly grown its presence in the cell analysis space and says i ...
Recent Tweets
-
@Dan5tanton: @bobby_gaspar of @orchard_tx confirms that design work is “well under way” for its CA site and that th… https://t.co/BKfCoAbqGI
2 days ago
-
A growing number of Big Pharma companies are abandoning diversification strategies and divesting non-core assets, l… https://t.co/viq22QNYZt
6 days ago
-
@Informa_LS is launching one of the biggest surveys of cell and #genetherapy professionals around the world on ana… https://t.co/8JSZXJl8s8
1 week ago
-
RT @Dan5tanton: Momenta says planned runs at manufacturing partner GSK could be reattributed to another product as it ends developm… https://t.co/vTUtW0H7CK
1 week ago
Trending
Multimedia
China's Emergence in Global Biopharma Manufacturing: Trends in the Chinese Biopharma Industry
Industry Innovators 2019-2020
Advancing Robust Manufacture of T-Cell Therapies: Application of Single-Use Stir-Tank Bioreactors
Ask the Experts
GMP Flow Cytometry: Applications, Considerations and Challenges
BPI Theater @ BIO 2019
Standardized Plasmids for Viral Vector Production